vr588
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 27, 2016 (NCT02740049)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vr588
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05006521 | Phase 1 | Jul 30, 2021 | Kinaset Therapeutics Inc, University of Manchester |
| NCT02740049 | Early Phase 1 (Phase 1) | Jan 27, 2016 | University of London, Vectura |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kinaset Therapeutics Inc | For profit | 1 | 1 | 1 | 2021 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Vectura | For profit | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1